Board summary
Key figures
30,725
Registered population
59.2% aged 18–64
20.4%
Aged 65+
ICB 20.0% · England 17.9%
13.9%
Ethnic minority (non-White)
11.7% Asian · England 9.6%
41.7%
In IMD quintile 1
ICB 30.6% · England 21.0%
~11,048
Core20 residents (est.)
Resident basis; registered basis ~13,765 · see page 3
5,656
Hypertension register
+4.27% in 3 yrs · England +5.60%
382
SMI register
36% of Hyndburn's
813
COPD register
Reviews -4.16% in 3 yrs
Forecast to 2030
6,203
Hypertension patients, 2030
+547 on today
71.1%
QRISK ≥20% on statins, 2030
+3.87pp over 3 yrs
5.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews lag England after three-year fall.
Annual asthma reviews reach 58.1% against 65.7% in England after falling 8.7% over 2023 to 2025, which may reflect recall capacity.
Non-frail diabetes HbA1c control trails England.
HbA1c control at or below 58 mmol/mol in non-frail diabetes is 52.3% (916 of 1,750 patients) versus 57.4% in England, suggesting recall needs.
Hypertension treatment to target exceeds England.
Hypertension treatment to target reaches 71.9% against 70.3% in England and 70.3% in the ICB, while diabetes with frailty HbA1c control reaches 86.2%.
Population, age and ethnicity
Patients aged 65+ reach 20.4% alongside concentrated Asian populations across member practices
Hyndburn Rural PCN plans services for 30,725 registered patients (practice lists sum to 30,728). Older patients aged 65+ make up 20.4% (6,255), exceeding Hyndburn (16.5%), the ICB (20.0%) and England (17.9%), while children aged 0–17 comprise 20.5% (6,287; Hyndburn 22.2%, ICB 19.6%, England 19.6%). Census resident data (not registered patients) indicates 11.7% Asian or Asian British residents, below Hyndburn (15.1%) but above the ICB (9.4%) and England (9.6%). This concentration reaches 64.6% at King Street Medical Ctr, 27.8% at Dr Bello's Surgery, and 26.3% at Dill Hall Surgery, against 2.7% at Higher Heys Surgery.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Hyndburn local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Hyndburn LA) | 1,997 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 52.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Hyndburn LA) | 1,099 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Hyndburn LA) | 14.2 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 41.7% of patients, spanning 67.8 percentage points between practices
Across the PCN, 41.7% of registered patients live in Core20 areas, below Hyndburn (54.1%) but above the ICB (30.6%) and England (21.0%). Practice shares span 67.8 pp from 32.2% to 100.0%. Concentration is highest at King Street Medical Ctr (100.0%) and Dr Bello's Surgery (81.2%), while volume concentrates at The Weavers Practice (3,088) and Great Harwood Medical Group (3,067). Practice estimates sum to 13,765 registered patients, differing from the 11,048 resident estimate. Delivery requires whole-practice pathways for high-concentration surgeries alongside targeted recall lists for high-volume practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
382
SMI register
1.15% recorded prevalence
268
Learning disability register
0.81% recorded prevalence
31
Care homes, 629 beds
In the PCN catchment
10.2%
Provide unpaid care
Hyndburn, Census 2021
The PCN records 268 patients with learning disabilities (0.8%; Hyndburn 0.9%, ICB 0.6%, England 0.6%) and 382 on the severe mental illness register (1.1%; Hyndburn 1.3%, ICB 1.2%, England 1.0%), alongside 31 catchment care homes with 629 beds. With learning disability and severe mental illness prevalence above England, protecting annual health checks and primary care liaison for these vulnerable cohorts is an operational priority.
Severe mental illness: physical health checks
SMI BMI recording is 76.9% (England 82.1%, ICB 76.8%), while 12-month blood pressure checks reached 81.6% (England 83.4%, ICB 79.8%). Across the 382-patient severe mental illness register, physical monitoring trails England benchmarks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,656
Hypertension register
+4.27%
Register growth, 3 yrs
Hyndburn +2.89% · England +5.60%
+2.07pp
BP control, under 80
≤140/90 · +2.30pp aged 80+
+547
More patients by 2030
Forecast 6,203 (18.56%)
Hypertension case-finding and control
Hyndburn Rural PCN records 5,656 patients on its hypertension register, a crude prevalence of 17.1% (Hyndburn 16.4%, ICB 17.2%, England 15.2%). Between 2023 and 2025, register growth of +4.3% trailed England (+5.6%) and the ICB (+6.3%), though exceeding Hyndburn (+2.9%). Blood pressure monitoring is 89.8% (Hyndburn 88.8%, ICB 89.0%, England 90.0%), and treatment to target reaches 71.9% (Hyndburn 70.1%, ICB 70.3%, England 70.3%). Across practices, prevalence ranges from 13.5% at King Street Medical Ctr to 19.0% at Great Harwood Medical Group. Although blood pressure control exceeds regional and national rates, slower register growth than England and lower prevalence at certain practices may indicate undetected hypertension, warranting targeted case finding.
Lipids and statins
For diabetes with history of CVD, statin therapy is 81.1% (Hyndburn 84.6%, ICB 84.1%, England 84.4%), after falling 0.4% over 2023 to 2025 (England +1.0%). For QRISK ≥ 20%, lipid-lowering therapy reaches 62.6% (Hyndburn 63.3%, ICB 61.4%, England 63.6%). Fewer high-risk patients receive lipid-lowering therapy than England rates imply, making secondary-prevention recall the priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 80,012 | £1.90 | £1.64 | £1.86 | £152,023 |
| Cardiovascular (all), 2025 | 111,314 | £3.09 | £3.38 | £3.33 | £343,960 |
In 2026, lipid-modifying drugs accounted for 80,012 prescribed items at £1.90 per item (Hyndburn £1.64, ICB £1.64, England £1.86), which is £20,803 more than at NHS Lancashire and South Cumbria Integrated Care Board's unit cost. Spending more per item than the ICB indicates an opportunity to review formulary adherence across practices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−8.67%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.62%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.6% (England 6.6%) across 2,372 patients, yet 12-month reviews fell 8.7% over 2023 to 2025 (England +4.4%) to 58.1% (England 65.7%), leaving about 990 patients unreviewed. Prescribing of asthma items for ages 5-19 reached 1,886 per 1,000 (England 1,488), whilst second-hand smoke recording for ages 6-19 is 69.4% (England 78.8%). COPD prevalence is 2.5% (England 1.9%), where reviews fell 4.2% over 2023 to 2025 (England +2.8%) to 73.8% (England 76.4%). These declines may reflect recall capacity, which an audit would test.
Cancer register and children's immunisation
Cancer register prevalence is 4.3% (1,437 patients; England 3.8%). In Q1 2025/26 childhood immunisations at age 5, MMR dose 1 reached 96.0% (England 91.7%) while dose 2 reached 90.7% (a 5.3 pp dose difference). The 4-in-1 pre-school booster reached 84.0% (ICB 85.2%), trailing 11 pp below the 95.0% target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
Across NHS Lancashire and South Cumbria ICB in 2022, 52.4% of cancers with a known stage (4,642 of 8,863) were diagnosed at stage 1 or 2, trailing England (55.3%) and 22.6 pp below the 75.0% national ambition by 2028. Known-stage completeness was 74.6% (8,863 of 11,883). Reaching the ambition requires about 2,010 extra early-stage cases annually across the ICB, where early-stage share fell 1.2 pp from 2013 to 2022. Locally, the cancer register grew 9.4% over 2023 to 2025 (England +9.0%) to 1,437 patients, while cervical screening fell 2.0% (England -1.0%) to 67.1%. These figures reflect ICB staging rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Lancashire Hospitals NHS Trust achieved 73.2% against the 85.0% cancer 62-day referral-to-treatment standard (11.8 pp below target), outperforming England (71.2%) but behind NHS Lancashire and South Cumbria Integrated Care Board (73.6%), Lancashire Teaching Hospitals NHS Foundation Trust (75.0%), and Northern Care Alliance NHS Foundation Trust (78.6%). On the 28-day faster diagnosis standard, East Lancashire Hospitals NHS Trust reached 81.5%, exceeding the 75.0% target by 6.5 pp, ahead of England (79.3%) and the ICB (78.4%), while Lancashire Teaching Hospitals NHS Foundation Trust reached 82.9%. Trust metrics reflect hospital performance, not PCN care.
| Pathways within standard (%) | East Lancashire | Lancashire | Northern Care Alliance | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 82.90 | 75.20 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 89.43 | 94.54 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 75.04 | 78.65 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Lancashire | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 0.43 | 2.41 | 5.09 | 21.40 |
| CT | 0.15 | 14.97 | 4.10 | 9.92 |
| Echocardiography | 0.00 | 13.85 | 31.48 | 28.48 |
| Colonoscopy | 0.95 | 0.00 | 40.04 | 30.83 |
| Gastroscopy | 1.16 | 0.00 | 36.48 | 29.02 |
| All 15 DM01 tests | 3.25 | 26.65 | 15.71 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026 (provisional), community health service contacts for Hyndburn borough residents totaled 126,445, with 72,000 contacts involving adults aged 65 and over, representing a 56.9% share of all recorded contacts. These figures capture borough-level community activity rather than practice-level consultations, highlighting high service use among older residents across the wider local authority.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF vaccination achievement spans 79.4 pp, from 0.0% at Dill Hall Surgery to 79.4% at Dr Bello's Surgery, against 55.2% in England. Overall achievement ranges from 9.2% at Dill Hall Surgery to 94.6% at Great Harwood Medical Group (England 92.5%). Personalised care adjustments reach 12.1% at The Clayton Medical Ctr. (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Higher Heys | 96 | 40.5 | 82.3% | 71.6% | 78.7% |
| Great Harwood | 104 | 32.2 | 39.9% | 61.8% | 77.5% |
| King Street | 104 | 100.0 | 75.5% | 71.1% | 65.5% |
| Clayton Medical | 97 | 45.6 | 40.5% | 57.8% | 65.5% |
| Dr Bello's Surgery | 88 | 81.2 | 65.1% | 74.3% | 64.1% |
| Weavers | 113 | 36.9 | 36.6% | 61.6% | 58.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 tracked trends trail England, led by falling chronic disease reviews
Across 25 tracked measures, 13 three-year trends trail England. The widest relative lags are in annual chronic disease reviews: heart failure reviews fell 15.3% over 2023 to 2025 (England +8.7%), asthma reviews fell 8.7% (England +4.4%), and COPD reviews fell 4.2% (England +2.8%). Conversely, three-year relative growth outpaced England for learning disability (+10.1% vs England +5.4%) and stroke (+4.6% vs England +2.3%), while smoking cessation support offers rose 2.4 pp (England +0.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Dementia register
COPD reviews
Asthma register
Diabetes HbA1c control
Smoking support (SMI)
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Hyndburn | Asset | PCN | Hyndburn |
|---|---|---|---|---|---|
| Care homes (catchment) | 31 (629 beds) | n/a | Schools (catchment) | 40 | n/a |
| Children's centres | 6 | 7 | Places of worship | 37 | 55 |
| Libraries | 4 | 5 | Primary schools (LA maintained) | 17 | 26 |
| Primary academies | 3 | 7 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Standardised asthma review and recall
Asthma 12-month reviews are 58.1% vs 65.7% in England (7.6 pp below) across 2,372 patients after falling 8.7% over 2023 to 2025 (England +4.4%), leaving 994 (about 990) unreviewed. For discussion: practices could run a single-template asthma recall combining annual reviews and smoking exposure checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Secondary-prevention statin and formulary review
In 2026, lipid-modifying drugs cost £1.90 per item across 80,012 items vs £1.64 in the ICB (£20,803 more), while statin therapy in diabetes with CVD is 81.1% (England 84.4%). For discussion: PCN pharmacists could review diabetes patients with CVD or QRISK ≥ 20% (62.6%) alongside practice formulary choices. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Non-frail diabetes HbA1c treatment intensification
In 2024/25, diabetes without frailty achieving HbA1c <= 58 mmol/mol is 52.3% (916 of 1,750 patients) vs 57.4% in England (5.0 pp below) and 56.2% in the ICB (3.8 pp below). For discussion: practices could run a targeted recall and medicines intensification audit for non-frail diabetes patients above 58 mmol/mol. Moderate effort to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored chronic disease recall (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster catch-up call-recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Standardised asthma review and recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Secondary-prevention statin and formulary review (p12) | Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026 · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
| Option 3 · Non-frail diabetes HbA1c treatment intensification (p12) | Diabetes without frailty: HbA1c at or below 58 mmol/mol · Diabetes with frailty: HbA1c at or below 75 mmol/mol · IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) | — | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
